"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA approves nivolumab (Opdivo) plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)

FDA approves nivolumab (Opdivo) plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)

15 May 2020 2:30 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software